Who is at risk for osteoporosis? What are the treatment initiation guidelines? Learn more about risk assessment and diagnosis, lifestyle interventions, the first-line bisphosphonates and denosumab, and the use of anabolic agents
ATTENTION! Kindly note that if you were in attendance of the live webinar you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record the 1 CPD point from the live webinar, invalidating any additional CPD points from the report.
 | Medical therapy for osteoporosis – what and when |
Quiz-summary
0 of 10 questions completed
Questions:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
Information
You have already completed the module before. Hence you can not start it again.
Module is loading…
You have to finish following quiz, to start this quiz:
Results
Results
Time has elapsed
Categories
- Not categorized 0%
-
Thank you, we will review your submission and notify you of your results via email.
If not received within 5 hours due to spam, don’t worry, it will show in your profile.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- Answered
- Review
- Question 1 of 10
1. Question
1. Which of the considerations below are important first steps in the prevention and treatment of osteoporosis?
- Question 2 of 10
2. Question
2. Which statement is incorrect? Consider treatment if:
- Question 3 of 10
3. Question
3. Which statement is incorrect? The FRAX model:
- Question 4 of 10
4. Question
4. Which statement is correct? MHT:
- Question 5 of 10
5. Question
5. Which statement is incorrect? Bisphosphonates:
- Question 6 of 10
6. Question
6. Which of these bisphosphonates is administered as an annual IV infusion?
- Question 7 of 10
7. Question
7. Which statement is incorrect? In terms of the side effects of bisphosphonates:
- Question 8 of 10
8. Question
8. Denosumab is not secreted by the kidneys and is a drug of choice for the patient with impaired kidney function:
- Question 9 of 10
9. Question
9. Which of these osteoporosis treatments is a selective oestrogen receptor modulator?
- Question 10 of 10
10. Question
10. Teriparatide should be reserved for patients over the age of 65 years with a T-score <-2 and ≥2 fragility fractures, or multiple fractures in an uninterpretable DXA, and considered in those who have failed treatment with bone active agents:
Do you like this? Share with a colleague
[DISPLAY_ULTIMATE_SOCIAL_ICONS]